A Phase 1/1b, Open-label Clinical Study of Intratumoral/Intralesional Administration of MK-4621/JetPEI as Monotherapy or in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2019
Price : $35 *
At a glance
- Drugs Pembrolizumab (Primary) ; RGT 100 (Primary) ; RGT 100 (Primary) ; RGT 100 (Primary)
- Indications Liver metastases; Solid tumours
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme
- 26 Feb 2019 Planned primary completion date changed from 14 Jan 2021 to 15 Apr 2021.
- 10 Jan 2019 Status changed from not yet recruiting to recruiting.
- 06 Dec 2018 Planned initiation date changed from 7 Dec 2018 to 17 Dec 2018.